Tumors of cluster 1 showed a significantly increased expression of multiple immune-related markers such as MPO, FCN1, CD200 and LEF1. Cluster 3 showed high expression of tumor promoters MAP3K13, MECOM and JAK2, predicting worse survival. The gene discussed is MAP3K13; the disease is neoplasm.